Skip to main content
. 2016 Oct 4;87(14):1464–1472. doi: 10.1212/WNL.0000000000003169

Figure 1. Percentage of CARE-MS I patients free from lesion activity and overall MRI disease activity.

Figure 1

Percentage of patients free from (A) new/enlarging T2-hyperintense lesions, (B) gadolinium (Gd)-enhancing lesions, and (C) new T1-hypointense lesions and (D) free from MRI disease activity. Freedom from MRI disease activity defined as the absence of new Gd-enhancing lesions and new/enlarging T2-hyperintense lesions. CARE-MS = Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis; CI = confidence interval; NS = no significant difference; SC IFN-β-1a = subcutaneous interferon β-1a. *p < 0.05; **p ≤ 0.0001.